HemaQuest Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 30
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: H92E6328D3BEN
Leaflet:

Download PDF Leaflet

HemaQuest Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “HemaQuest Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • HemaQuest Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of HemaQuest Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of HemaQuest Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the HemaQuest Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate HemaQuest Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of HemaQuest Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the HemaQuest Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with HemaQuest Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of HemaQuest Pharmaceuticals, Inc. and identify potential opportunities in those areas.
HemaQuest Pharmaceuticals, Inc. Snapshot
HemaQuest Pharmaceuticals, Inc. Overview
Key Information
Key Facts
HemaQuest Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
HemaQuest Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
HemaQuest Pharmaceuticals, Inc. – Pipeline Products Glance
HemaQuest Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
HemaQuest Pharmaceuticals, Inc. – Drug Profiles
HQK-1001
  Product Description
  Mechanism of Action
  R&D Progress
HQK-1004 + Ganciclovir
  Product Description
  Mechanism of Action
  R&D Progress
HQK-1004 + Ganciclovir + Valganciclovir
  Product Description
  Mechanism of Action
  R&D Progress
HemaQuest Pharmaceuticals, Inc. – Pipeline Analysis
HemaQuest Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
HemaQuest Pharmaceuticals, Inc. Pipeline Products By Target
HemaQuest Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
HemaQuest Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Aug 11, 2010: HemaQuest Initiates Phase II Clinical Trial Of HQK-1004In EBV-Related Malignancies
Dec 08, 2009: HemaQuest Pharmaceuticals Presents Promising Results In Sickle Cell Disease And Beta Thalassemia
Dec 08, 2009: HemaQuest Pharmaceuticals Presents Promising Results In Sickle Cell Disease And Beta Thalassemia
May 26, 2009: HemaQuest Initiates Clinical Trials In Sickle Cell Disease And Beta Thalassemia
May 26, 2009: HemaQuest Initiates Clinical Trials In Sickle Cell Disease And Beta Thalassemia
Mar 25, 2009: HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations For Therapeutic To Treat Hemoglobin Disorders
Mar 25, 2009: HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations For Therapeutic To Treat Hemoglobin Disorders
Dec 09, 2008: HemaQuest Pharmaceuticals Announces Clinical Progress On New Sickle Cell Anemia Drug
Nov 04, 2008: HemaQuest Pharmaceuticals Receives Orphan Drug Designations For Therapeutic To Treat Hemoglobin Disorders
Nov 04, 2008: HemaQuest Pharmaceuticals Receives Orphan Drug Designations For Therapeutic To Treat Hemoglobin Disorders
Financial Deals Landscape
HemaQuest Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
HemaQuest Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
HemaQuest Pharmaceuticals Secures $6 Million In Venture Financing
HemaQuest Pharmaceuticals Secures $20 Million In Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 30

LIST OF TABLES

HemaQuest Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
HemaQuest Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
HemaQuest Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
HemaQuest Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
HemaQuest Pharmaceuticals, Inc. - Phase II, 2010
HemaQuest Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
HemaQuest Pharmaceuticals, Inc. - Pipeline By Target, 2010
HemaQuest Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2010
HemaQuest Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
HemaQuest Pharmaceuticals Secures $6 Million In Venture Financing
HemaQuest Pharmaceuticals Secures $20 Million In Series A Financing 27

LIST OF FIGURES

HemaQuest Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
HemaQuest Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
HemaQuest Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
HemaQuest Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
HemaQuest Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
HemaQuest Pharmaceuticals, Inc. - Pipeline By Target, 2010 16

Ask Your Question

HemaQuest Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: